{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:48:11Z","timestamp":1794552491852,"version":"4.9.1"},"reference-count":130,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>In kidney transplantation, ongoing alloimmune processes\u2014commonly triggered by HLA incompatibilities\u2014can trigger chronic transplant rejection, affecting the microcirculation and the tubulointerstitium. Continuous inflammation may lead to progressive, irreversible graft injury, culminating in graft dysfunction and accelerated transplant failure. Numerous experimental and translational studies have delineated a complex interplay of different immune mechanisms driving rejection, with antibody-mediated rejection (AMR) being an extensively studied rejection variant. In microvascular inflammation, a hallmark lesion of AMR, natural killer (NK) cells have emerged as pivotal effector cells. Their essential role is supported by immunohistologic evidence, bulk and spatial transcriptomics, and functional genetics. Despite significant research efforts, a substantial unmet need for approved rejection therapies persists, with many trials yielding negative outcomes. However, several promising therapies are currently under investigation, including felzartamab, a monoclonal antibody targeting the surface molecule CD38, which is highly expressed in NK cells and antibody-producing plasma cells. In an exploratory phase 2 trial in late AMR, this compound has demonstrated potential in resolving molecular and morphologic rejection activity and injury, predominantly by targeting NK cell effector function. These findings inspire hope for effective treatments and emphasize the necessity of further pivotal trials focusing on chronic transplant rejection.<\/jats:p>","DOI":"10.1097\/tp.0000000000005187","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:02:24Z","timestamp":1724803344000},"page":"610-621","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":45,"title":["Chronic Rejection After Kidney Transplantation"],"prefix":"10.1097","volume":"109","author":[{"given":"Matthias","family":"Diebold","sequence":"first","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."},{"name":"Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, University of Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina A.","family":"Mayer","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Hidalgo","sequence":"additional","affiliation":[{"name":"HLA Laboratory, Division of Transplantation, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Kozakowski","sequence":"additional","affiliation":[{"name":"Department of Pathology, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Budde","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg A.","family":"B\u00f6hmig","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"R1-20250325","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.5888\/pcd10.120239","article-title":"Defining and measuring chronic conditions: imperatives for research, policy, program, and practice.","volume":"10","author":"Goodman","year":"2013","journal-title":"Prev Chronic Dis"},{"key":"R2-20250325","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1097\/TP.0000000000002366","article-title":"A 2018 reference guide to the Banff classification of renal allograft pathology.","volume":"102","author":"Roufosse","year":"2018","journal-title":"Transplantation"},{"key":"R3-20250325","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ajt.2023.10.016","article-title":"The Banff 2022 Kidney Meeting Report: reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics.","volume":"24","author":"Naesens","year":"2024","journal-title":"Am J Transplant"},{"key":"R4-20250325","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.","volume":"18","author":"Haas","year":"2018","journal-title":"Am J Transplant"},{"key":"R5-20250325","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/ajt.16419","article-title":"Does the definition of chronic active T cell-mediated rejection need revisiting?","volume":"21","author":"Naesens","year":"2021","journal-title":"Am J Transplant"},{"key":"R6-20250325","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MOT.0000000000001130","article-title":"Emerging phenotypes in kidney transplant rejection.","volume":"29","author":"Mengel","year":"2024","journal-title":"Curr Opin Organ Transplant"},{"key":"R7-20250325","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1111\/ajt.16474","article-title":"Revisiting the changes in the Banff classification for antibody-mediated rejection after kidney transplantation.","volume":"21","author":"Callemeyn","year":"2021","journal-title":"Am J Transplant"},{"key":"R8-20250325","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1681\/ASN.2020030306","article-title":"Transcriptional changes in kidney allografts with histology of antibody-mediated rejection without anti-HLA donor-specific antibodies.","volume":"31","author":"Callemeyn","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"R9-20250325","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1111\/ajt.17092","article-title":"Molecular diagnosis of ABMR with or without donor-specific antibody in kidney transplant biopsies: differences in timing and intensity but similar mechanisms and outcomes.","volume":"22","author":"Halloran","year":"2022","journal-title":"Am J Transplant"},{"key":"R10-20250325","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/TP.0000000000004624","article-title":"The molecular phenotype of kidney transplants: insights from the MMDx project.","volume":"108","author":"Halloran","year":"2024","journal-title":"Transplantation"},{"key":"R11-20250325","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1681\/ASN.2021040433","article-title":"Donor-specific antibody is associated with increased expression of rejection transcripts in renal transplant biopsies classified as no rejection.","volume":"32","author":"Madill-Thomsen","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"R12-20250325","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/ajt.15178","article-title":"Molecular phenotype of kidney transplant indication biopsies with inflammation in scarred areas.","volume":"19","author":"Halloran","year":"2019","journal-title":"Am J Transplant"},{"key":"R13-20250325","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/ajt.14565","article-title":"T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts.","volume":"18","author":"Lefaucheur","year":"2018","journal-title":"Am J Transplant"},{"key":"R14-20250325","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/ajt.14609","article-title":"The causes, significance and consequences of inflammatory fibrosis in kidney transplantation: the Banff i-IFTA lesion.","volume":"18","author":"Nankivell","year":"2018","journal-title":"Am J Transplant"},{"key":"R15-20250325","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/ajt.16352","article-title":"i-IFTA and chronic active T cell-mediated rejection: a tale of 2 (DeKAF) cohorts.","volume":"21","author":"Helgeson","year":"2021","journal-title":"Am J Transplant"},{"key":"R16-20250325","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.kint.2021.03.027","article-title":"Chronic active T cell-mediated rejection is variably responsive to immunosuppressive therapy.","volume":"100","author":"Kung","year":"2021","journal-title":"Kidney Int"},{"key":"R17-20250325","article-title":"Banff 2022 Kidney Commentary: reflections and future directions.","author":"Rabant","journal-title":"Transplantation"},{"key":"R18-20250325","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1056\/NEJMra1802677","article-title":"Antibody-mediated rejection of solid-organ allografts.","volume":"379","author":"Loupy","year":"2018","journal-title":"N Engl J Med"},{"key":"R19-20250325","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41581-023-00791-0","article-title":"Translating B cell immunology to the treatment of antibody-mediated allograft rejection.","volume":"20","author":"Heeger","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"R20-20250325","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S0140-6736(18)32473-5","article-title":"Contribution of non-HLA incompatibility between donor and recipient to kidney allograft survival: genome-wide analysis in a prospective cohort.","volume":"393","author":"Reindl-Schwaighofer","year":"2019","journal-title":"Lancet"},{"key":"R21-20250325","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1056\/NEJMoa035717","article-title":"Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.","volume":"352","author":"Dragun","year":"2005","journal-title":"N Engl J Med"},{"key":"R22-20250325","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3389\/fimmu.2020.01454","article-title":"The role of natural killer cells in the immune response in kidney transplantation.","volume":"11","author":"Pontrelli","year":"2020","journal-title":"Front Immunol"},{"key":"R23-20250325","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK cells and cancer: you can teach innate cells new tricks.","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"R24-20250325","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1038\/s41467-019-13113-5","article-title":"Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants.","volume":"10","author":"Koenig","year":"2019","journal-title":"Nat Commun"},{"key":"R25-20250325","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","article-title":"The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy.","volume":"8","author":"Paul","year":"2017","journal-title":"Front Immunol"},{"key":"R26-20250325","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1182\/blood-2012-01-380121","article-title":"Properties of mouse and human IgG receptors and their contribution to disease models.","volume":"119","author":"Bruhns","year":"2012","journal-title":"Blood"},{"key":"R27-20250325","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1600-6143.2011.03836.x","article-title":"A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody.","volume":"12","author":"Hirohashi","year":"2012","journal-title":"Am J Transplant"},{"key":"R28-20250325","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.kint.2016.02.030","article-title":"Natural killer cells play a critical role in mediating inflammation and graft failure during antibody-mediated rejection of kidney allografts.","volume":"89","author":"Kohei","year":"2016","journal-title":"Kidney Int"},{"key":"R29-20250325","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1097\/TP.0000000000000665","article-title":"Natural killer cells mediate long-term kidney allograft injury.","volume":"99","author":"Zhang","year":"2015","journal-title":"Transplantation"},{"key":"R30-20250325","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.kint.2018.08.041","article-title":"In the absence of natural killer cell activation donor-specific antibody mediates chronic, but not acute, kidney allograft rejection.","volume":"95","author":"Yagisawa","year":"2019","journal-title":"Kidney Int"},{"key":"R31-20250325","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/j.1600-6143.2010.03201.x","article-title":"NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection.","volume":"10","author":"Hidalgo","year":"2010","journal-title":"Am J Transplant"},{"key":"R32-20250325","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/ajt.13115","article-title":"The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors.","volume":"15","author":"Venner","year":"2015","journal-title":"Am J Transplant"},{"key":"R33-20250325","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.kint.2018.08.027","article-title":"Natural killer cell infiltration is discriminative for antibody-mediated rejection and predicts outcome after kidney transplantation.","volume":"95","author":"Yazdani","year":"2019","journal-title":"Kidney Int"},{"key":"R34-20250325","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1038\/s41467-023-39859-7","article-title":"Transcriptional and spatial profiling of the kidney allograft unravels a central role for FcyRIII+ innate immune cells in rejection.","volume":"14","author":"Lamarthee","year":"2023","journal-title":"Nat Commun"},{"key":"R35-20250325","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1681\/ASN.0000000000000350","article-title":"The clinical relevance of the infiltrating immune cell composition in kidney transplant rejection.","volume":"35","author":"Vaulet","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"R36-20250325","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3389\/fimmu.2016.00288","article-title":"Antibody-dependent NK cell activation is associated with late kidney allograft dysfunction and the complement-independent alloreactive potential of donor-specific antibodies.","volume":"7","author":"Legris","year":"2016","journal-title":"Front Immunol"},{"key":"R37-20250325","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1111\/ajt.14710","article-title":"Functional Fc gamma receptor gene polymorphisms and donor-specific antibody-triggered microcirculation inflammation.","volume":"18","author":"Arnold","year":"2018","journal-title":"Am J Transplant"},{"key":"R38-20250325","doi-asserted-by":"crossref","first-page":"724331","DOI":"10.3389\/fimmu.2021.724331","article-title":"Functional Fc gamma receptor gene polymorphisms and long-term kidney allograft survival.","volume":"12","author":"Wahrmann","year":"2021","journal-title":"Front Immunol"},{"key":"R39-20250325","doi-asserted-by":"crossref","first-page":"7903","DOI":"10.1038\/s41598-021-86943-3","article-title":"The FCGR3A 158 V\/V-genotype is associated with decreased survival of renal allografts with chronic active antibody-mediated rejection.","volume":"11","author":"Litjens","year":"2021","journal-title":"Sci Rep"},{"key":"R40-20250325","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ajt.2023.12.005","article-title":"Natural killer cell functional genetics and donor-specific antibody-triggered microvascular inflammation.","volume":"24","author":"Diebold","year":"2024","journal-title":"Am J Transplant"},{"key":"R41-20250325","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1681\/ASN.2020111558","article-title":"Missing self-induced microvascular rejection of kidney allografts: a population-based study.","volume":"32","author":"Callemeyn","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"R42-20250325","doi-asserted-by":"crossref","first-page":"829228","DOI":"10.3389\/fimmu.2022.829228","article-title":"Deletion of the natural killer cell receptor NKG2C encoding KLR2C gene and kidney transplant outcome.","volume":"13","author":"Vietzen","year":"2022","journal-title":"Front Immunol"},{"key":"R43-20250325","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.3390\/molecules25204844","article-title":"The circular life of human CD38: from basic science to clinics and back.","volume":"25","author":"Horenstein","year":"2020","journal-title":"Molecules"},{"key":"R44-20250325","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa2400763","article-title":"A randomized phase 2 trial of Felzartamab in antibody-mediated rejection.","volume":"391","author":"Mayer","year":"2024","journal-title":"N Engl J Med"},{"key":"R45-20250325","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1097\/TP.0000000000002267","article-title":"Novel approaches to block complement.","volume":"102","author":"B\u00f6hmig","year":"2018","journal-title":"Transplantation"},{"key":"R46-20250325","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.","volume":"11","author":"Stegall","year":"2011","journal-title":"Am J Transplant"},{"key":"R47-20250325","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/ajt.14528","article-title":"Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection\u2014results from a first-in-patient phase 1 trial.","volume":"18","author":"Eskandary","year":"2018","journal-title":"Am J Transplant"},{"key":"R48-20250325","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1681\/ASN.2008030279","article-title":"C4d deposition without rejection correlates with reduced early scarring in ABO-incompatible renal allografts.","volume":"20","author":"Haas","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R49-20250325","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MOT.0b013e32835d4daf","article-title":"Pathology of C4d-negative antibody-mediated rejection in renal allografts.","volume":"18","author":"Haas","year":"2013","journal-title":"Curr Opin Organ Transplant"},{"key":"R50-20250325","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1302506","article-title":"Complement-binding anti-HLA antibodies and kidney-allograft survival.","volume":"369","author":"Loupy","year":"2013","journal-title":"N Engl J Med"},{"key":"R51-20250325","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/TP.0000000000001195","article-title":"Diagnostic contribution of donor-specific antibody characteristics to uncover late silent antibody-mediated rejection\u2014results of a cross-sectional screening study.","volume":"101","author":"Eskandary","year":"2017","journal-title":"Transplantation"},{"key":"R52-20250325","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1681\/ASN.V1071582","article-title":"Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages.","volume":"10","author":"Grimm","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"R53-20250325","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1600-6143.2006.01634.x","article-title":"The cellular lesion of humoral rejection: predominant recruitment of monocytes to peritubular and glomerular capillaries.","volume":"7","author":"Fahim","year":"2007","journal-title":"Am J Transplant"},{"key":"R54-20250325","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.kint.2017.01.029","article-title":"Macrophage density in early surveillance biopsies predicts future renal transplant function.","volume":"92","author":"Brasen","year":"2017","journal-title":"Kidney Int"},{"key":"R55-20250325","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/ndt\/gfp045","article-title":"Monocytes\/macrophages in kidney allograft intimal arteritis: no association with markers of humoral rejection or with inferior outcome.","volume":"24","author":"Kozakowski","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R56-20250325","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1097\/TP.0b013e318188d433","article-title":"Depletion of cells of monocyte lineage prevents loss of renal microvasculature in murine kidney transplantation.","volume":"86","author":"Qi","year":"2008","journal-title":"Transplantation"},{"key":"R57-20250325","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/j.1600-6143.2007.01997.x","article-title":"Macrophage depletion suppresses cardiac allograft vasculopathy in mice.","volume":"7","author":"Kitchens","year":"2007","journal-title":"Am J Transplant"},{"key":"R58-20250325","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1172\/JCI74370","article-title":"Non-self recognition by monocytes initiates allograft rejection.","volume":"124","author":"Oberbarnscheidt","year":"2014","journal-title":"J Clin Invest"},{"key":"R59-20250325","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.kint.2017.10.006","article-title":"Donor SIRP-alpha polymorphisms: widening the innate-to-adaptive continuum in allograft rejection.","volume":"92","author":"Menon","year":"2017","journal-title":"Kidney Int"},{"key":"R60-20250325","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1126\/science.aax4040","article-title":"PIRs mediate innate myeloid cell memory to nonself MHC molecules.","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"R61-20250325","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.kint.2021.11.029","article-title":"Allorecognition and the spectrum of kidney transplant rejection.","volume":"101","author":"Callemeyn","year":"2022","journal-title":"Kidney Int"},{"key":"R62-20250325","article-title":"Targeting macrophages in organ transplantation: a step toward personalized medicine.","author":"Owen","journal-title":"Transplantation"},{"key":"R63-20250325","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.kint.2023.11.026","article-title":"Multiomic profiling of transplant glomerulopathy reveals a novel T-cell dominant subclass.","volume":"105","author":"Cristoferi","year":"2024","journal-title":"Kidney Int"},{"key":"R64-20250325","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ajt.2022.12.018","article-title":"Microvascular inflammation in the absence of human leukocyte antigen-donor-specific antibody and C4d: an orphan category in Banff classification with cytotoxic T and natural killer cell infiltration.","volume":"23","author":"Buxeda","year":"2023","journal-title":"Am J Transplant"},{"key":"R65-20250325","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.kint.2023.11.012","article-title":"Transcriptomic signatures of chronic active antibody-mediated rejection deciphered by RNA sequencing of human kidney allografts.","volume":"105","author":"Shah","year":"2024","journal-title":"Kidney Int"},{"key":"R66-20250325","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1681\/ASN.2013080848","article-title":"Expansion of highly differentiated cytotoxic terminally differentiated effector memory CD8+ T cells in a subset of clinically stable kidney transplant recipients: a potential marker for late graft dysfunction.","volume":"25","author":"Yap","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"R67-20250325","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1681\/ASN.2019080847","article-title":"Terminally differentiated effector memory CD8(+) T cells identify kidney transplant recipients at high risk of graft failure.","volume":"31","author":"Jacquemont","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"R68-20250325","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.kint.2024.01.009","article-title":"Back to the future: the uncharted role of T cells in chronic and unexplained microvascular inflammation.","volume":"105","author":"Callemeyn","year":"2024","journal-title":"Kidney Int"},{"key":"R69-20250325","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1111\/j.1600-6143.2009.02819.x","article-title":"Effect of antibodies on endothelium.","volume":"9","author":"Zhang","year":"2009","journal-title":"Am J Transplant"},{"key":"R70-20250325","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.4049\/jimmunol.2000535","article-title":"Ligation of HLA class I molecules induces YAP activation through Src in human endothelial cells.","volume":"205","author":"Anwar","year":"2020","journal-title":"J Immunol"},{"key":"R71-20250325","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ajt.2023.10.020","article-title":"Human leukocyte antigen class I antibody-activated endothelium promotes CD206+ M2 macrophage polarization and MMP9 secretion through TLR4 signaling and P-selectin in a model of antibody-mediated rejection and allograft vasculopathy.","volume":"24","author":"Nevarez-Mejia","year":"2024","journal-title":"Am J Transplant"},{"key":"R72-20250325","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.kint.2019.04.023","article-title":"HLA-DQ alloantibodies directly activate the endothelium and compromise differentiation of FoxP3(high) regulatory T lymphocytes.","volume":"96","author":"Cross","year":"2019","journal-title":"Kidney Int"},{"key":"R73-20250325","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.kint.2021.09.029","article-title":"Non-HLA antibodies targeting angiotensin II type 1 receptor and endothelin-1 type A receptors induce endothelial injury via beta2-arrestin link to mTOR pathway.","volume":"101","author":"Catar","year":"2022","journal-title":"Kidney Int"},{"key":"R74-20250325","doi-asserted-by":"crossref","first-page":"e14320","DOI":"10.1111\/ctr.14320","article-title":"Incidence, risk factors, treatment, and consequences of antibody-mediated kidney transplant rejection: a systematic review.","volume":"35","author":"Hart","year":"2021","journal-title":"Clin Transplant"},{"key":"R75-20250325","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.","volume":"12","author":"Sellar\u00e9s","year":"2012","journal-title":"Am J Transplant"},{"key":"R76-20250325","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1681\/ASN.2020081215","article-title":"Exploring the complexity of death-censored kidney allograft failure.","volume":"32","author":"Mayrdorfer","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"R77-20250325","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/TP.0000000000003274","article-title":"Change in estimated GFR and risk of allograft failure in patients diagnosed with late active antibody-mediated rejection following kidney transplantation.","volume":"105","author":"Irish","year":"2021","journal-title":"Transplantation"},{"key":"R78-20250325","doi-asserted-by":"crossref","first-page":"e14337","DOI":"10.1111\/ctr.14337","article-title":"Incidence, risk factors, and long-term outcomes associated with antibody-mediated rejection\u2014the long-term Deterioration of Kidney Allograft Function (DeKAF) prospective cohort study.","volume":"35","author":"Hart","year":"2021","journal-title":"Clin Transplant"},{"key":"R79-20250325","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/14737167.2024.2305140","article-title":"Economic and humanistic burden in kidney transplant rejection: a literature review.","volume":"24","author":"Moss","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"R80-20250325","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1080\/13696998.2021.1964267","article-title":"Cost, healthcare utilization, and outcomes of antibody-mediated rejection in kidney transplant recipients in the US.","volume":"24","author":"Hart","year":"2021","journal-title":"J Med Econ"},{"key":"R81-20250325","doi-asserted-by":"crossref","first-page":"817127","DOI":"10.3389\/fmed.2022.817127","article-title":"Early estimated glomerular filtration rate trajectories after kidney transplant biopsy as a surrogate endpoint for graft survival in late antibody-mediated rejection.","volume":"9","author":"Borski","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R82-20250325","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.kint.2022.09.030","article-title":"A Banff-based histologic chronicity index is associated with graft loss in patients with a kidney transplant and antibody-mediated rejection.","volume":"103","author":"Haas","year":"2023","journal-title":"Kidney Int"},{"key":"R83-20250325","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1681\/ASN.2022030290","article-title":"Data-driven chronic allograft phenotypes: a novel and validated complement for histologic assessment of kidney transplant biopsies.","volume":"33","author":"Vaulet","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"R84-20250325","doi-asserted-by":"crossref","first-page":"12135","DOI":"10.3389\/ti.2023.12135","article-title":"Morphologic and molecular features of antibody-mediated transplant rejection: pivotal role of molecular injury as an independent predictor of renal allograft functional decline.","volume":"36","author":"Herz","year":"2023","journal-title":"Transpl Int"},{"key":"R85-20250325","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/TP.0000000000004550","article-title":"On a long and winding road: alloantibodies in organ transplantation.","volume":"107","author":"B\u00f6hmig","year":"2023","journal-title":"Transplantation"},{"key":"R86-20250325","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1681\/ASN.2012070664","article-title":"Donor-specific antibodies adversely affect kidney allograft outcomes.","volume":"23","author":"Mohan","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R87-20250325","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/ajt.12786","article-title":"Quantifying the risk of incompatible kidney transplantation: a multicenter study.","volume":"14","author":"Orandi","year":"2014","journal-title":"Am J Transplant"},{"key":"R88-20250325","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/TP.0b013e3181da1cc3","article-title":"Combined posttransplant prophylactic IVIg\/anti-CD 20\/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study.","volume":"89","author":"Loupy","year":"2010","journal-title":"Transplantation"},{"key":"R89-20250325","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1097\/TP.0000000000001650","article-title":"Long-term outcomes of kidney transplantation in patients with high levels of preformed DSA: the necker high-risk transplant program.","volume":"101","author":"Amrouche","year":"2017","journal-title":"Transplantation"},{"key":"R90-20250325","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.humimm.2013.06.022","article-title":"Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches.","volume":"74","author":"Yamanaga","year":"2013","journal-title":"Hum Immunol"},{"key":"R91-20250325","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1681\/ASN.2017070818","article-title":"A randomized trial of Bortezomib in Late Antibody-Mediated Rejection (BORTEJECT).","volume":"29","author":"Eskandary","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"R92-20250325","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1681\/ASN.2020071106","article-title":"A randomized clinical trial of Anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection.","volume":"32","author":"Doberer","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"R93-20250325","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1111\/ajt.15414","article-title":"Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation.","volume":"19","author":"Senev","year":"2019","journal-title":"Am J Transplant"},{"key":"R94-20250325","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/TP.0b013e31817c4cb8","article-title":"Human leukocyte antigen antibodies and chronic rejection: from association to causation.","volume":"86","author":"Terasaki","year":"2008","journal-title":"Transplantation"},{"key":"R95-20250325","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/j.1600-6143.2009.02800.x","article-title":"De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure.","volume":"9","author":"Hidalgo","year":"2009","journal-title":"Am J Transplant"},{"key":"R96-20250325","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1681\/ASN.2016070797","article-title":"Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients.","volume":"28","author":"Aubert","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R97-20250325","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.kint.2016.10.040","article-title":"Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent\/recurrent versus de novo donor-specific antibodies.","volume":"91","author":"Haas","year":"2017","journal-title":"Kidney Int"},{"key":"R98-20250325","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1600-6143.2012.04013.x","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant.","volume":"12","author":"Wiebe","year":"2012","journal-title":"Am J Transplant"},{"key":"R99-20250325","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1111\/ajt.14393","article-title":"Donor-recipient matching based on predicted indirectly recognizable HLA epitopes independently predicts the incidence of de novo donor-specific HLA antibodies following renal transplantation.","volume":"17","author":"Lachmann","year":"2017","journal-title":"Am J Transplant"},{"key":"R100-20250325","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1111\/ajt.15177","article-title":"HLA-DR\/DQ molecular mismatch: a prognostic biomarker for primary alloimmunity.","volume":"19","author":"Wiebe","year":"2019","journal-title":"Am J Transplant"},{"key":"R101-20250325","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1111\/ajt.13341","article-title":"The synergistic effect of class II HLA epitope-mismatch and nonadherence on acute rejection and graft survival.","volume":"15","author":"Wiebe","year":"2015","journal-title":"Am J Transplant"},{"key":"R102-20250325","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/tri.12544","article-title":"Long-term outcome of belatacept therapy in de novo kidney transplant recipients\u2014a case-match analysis.","volume":"28","author":"Schwarz","year":"2015","journal-title":"Transplant Inter"},{"key":"R103-20250325","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/ajt.14721","article-title":"De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.","volume":"18","author":"Bray","year":"2018","journal-title":"Am J Transplant"},{"key":"R104-20250325","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/TP.0000000000004646","article-title":"Cellular immunobiology and molecular mechanisms in alloimmunity-pathways of immunosuppression.","volume":"108","author":"Schrezenmeier","year":"2024","journal-title":"Transplantation"},{"key":"R105-20250325","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 Expert Consensus From the Transplantion Society Working Group.","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"},{"key":"R106-20250325","doi-asserted-by":"crossref","first-page":"101819","DOI":"10.1016\/j.eclinm.2022.101819","article-title":"Optimized immunosuppression to prevent graft failure in renal transplant recipients with HLA antibodies (OuTSMART): a randomised controlled trial.","volume":"56","author":"Stringer","year":"2023","journal-title":"EClinicalMed"},{"key":"R107-20250325","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/ajt.14520","article-title":"Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: a multicenter, prospective, randomized, double-blind clinical trial.","volume":"18","author":"Moreso","year":"2018","journal-title":"Am J Transplant"},{"key":"R108-20250325","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fimmu.2020.00079","article-title":"Effect of optimized immunosuppression (including rituximab) on anti-donor alloresponses in patients with chronically rejecting renal allografts.","volume":"11","author":"Shiu","year":"2020","journal-title":"Front Immunol"},{"key":"R109-20250325","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1186\/s13063-022-06897-3","article-title":"Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design.","volume":"23","author":"Nickerson","year":"2022","journal-title":"Trials"},{"key":"R110-20250325","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13063-024-08020-0","article-title":"Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study).","volume":"25","author":"Streichart","year":"2024","journal-title":"Trials"},{"key":"R111-20250325","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/ajt.14001","article-title":"Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial.","volume":"17","author":"Kulkarni","year":"2017","journal-title":"Am J Transplant"},{"key":"R112-20250325","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1681\/ASN.2016070727","article-title":"Humoral compensation after bortezomib treatment of allosensitized recipients.","volume":"28","author":"Kwun","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R113-20250325","article-title":"Bortezomib in Rejection of Kidney Transplants (TRIBUTE). Bethesda (MD): U.S. National Library of Medicine; 2014 [updated September 16, 2020; cited May 2, 2024]."},{"key":"R114-20250325","article-title":"Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients (IMAGINE). Bethesda (MD): U.S. National Library of Medicine; 2018 [updated April 24, 2024; cited May 2, 2024]."},{"key":"R115-20250325","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s13063-022-06198-9","article-title":"Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.","volume":"23","author":"Mayer","year":"2022","journal-title":"Trials"},{"key":"R116-20250325","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1681\/ASN.2018121254","article-title":"Daratumumab in sensitized kidney transplantation: potentials and limitations of experimental and clinical use.","volume":"30","author":"Kwun","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"R117-20250325","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1053\/j.ajkd.2022.11.010","article-title":"Daratumumab use prior to kidney transplant and T Cell-mediated rejection: a case report.","volume":"81","author":"Scalzo","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"R118-20250325","article-title":"BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR). Bethesda (MD): U.S. National Library of Medicine; 2021 [updated Mar 15, 2024; cited May 1, 2024]."},{"key":"R119-20250325","article-title":"Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection (FOSTAMR). Bethesda (MD): U.S. National Library of Medicine; 2019 [updated October 4, 2021; cited March 22, 2024]."},{"key":"R120-20250325","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1038\/s41598-022-06413-2","article-title":"Inhibition of spleen tyrosine kinase decreases donor specific antibody levels in a rat model of sensitization.","volume":"12","author":"Tempest-Roe","year":"2022","journal-title":"Sci Rep"},{"key":"R121-20250325","first-page":"547","article-title":"Photopheresis abates the anti-HLA antibody titer and renal failure progression in chronic antibody-mediated rejection.","volume":"10","author":"Gregorini","year":"2021","journal-title":"Biology (Basel)"},{"key":"R122-20250325","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1111\/tri.14006","article-title":"Successful treatment of acute kidney allograft rejection using extracorporeal photopheresis in the context of post-transplant lymphoproliferative diseases: three successive cases.","volume":"34","author":"Augusto","year":"2021","journal-title":"Transpl Int"},{"key":"R123-20250325","article-title":"Impact of ExtraCorporeal Phototherapy (ECP) on Auxiliary Follicular T-lymphocytes and Circulating B-lymphocytes During Chronic AntiBody-Mediated Rejection in Kidney Transplantation. (IPECAM). Bethesda (MD): U.S. National Library of Medicine; 2021 [updated May 3, 2021; cited March 25, 2024]."},{"key":"R124-20250325","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"R125-20250325","doi-asserted-by":"crossref","first-page":"10139","DOI":"10.3389\/ti.2022.10139","article-title":"Allograft function as endpoint for clinical trials in kidney transplantation.","volume":"35","author":"Hilbrands","year":"2022","journal-title":"Transpl Int"},{"key":"R126-20250325","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/tri.13970","article-title":"Diagnostic value of donor-derived cell-free DNA to predict antibody-mediated rejection in donor-specific antibody-positive renal allograft recipients.","volume":"34","author":"Mayer","year":"2021","journal-title":"Transpl Int"},{"key":"R127-20250325","doi-asserted-by":"crossref","first-page":"10136","DOI":"10.3389\/ti.2022.10136","article-title":"Surrogate endpoints for late kidney transplantation failure.","volume":"35","author":"Naesens","year":"2022","journal-title":"Transpl Int"},{"key":"R128-20250325","doi-asserted-by":"crossref","first-page":"10137","DOI":"10.3389\/ti.2022.10137","article-title":"Rationale for surrogate endpoints and conditional marketing authorization of new therapies for kidney transplantation.","volume":"35","author":"Naesens","year":"2022","journal-title":"Transpl Int"},{"key":"R129-20250325","doi-asserted-by":"crossref","first-page":"l4923","DOI":"10.1136\/bmj.l4923","article-title":"Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study.","volume":"366","author":"Loupy","year":"2019","journal-title":"BMJ"},{"key":"R130-20250325","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.ajt.2023.04.018","article-title":"Qualifying a novel clinical trial endpoint (iBOX) predictive of long-term kidney transplant outcomes.","volume":"23","author":"Klein","year":"2023","journal-title":"Am J Transplant"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T03:32:05Z","timestamp":1743132725000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":130,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005187","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]}}}